GSK Goes To The Heart Of The Problem With Outcomes Study For Darapladib
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline is applying a lesson the pharmaceutical industry learned from recent events in cardiovascular drug development: do an outcomes study, and start it early